

Letter of Intent for strategic partnership / Vaccentis and TrueMed join forces to advance cancer vaccine

Thursday 9 October, 2025

Vaccntis, a Zurich based biotech company specializing in the development of therapeutic protein-based tumor vaccines, has signed a letter of intent with TrueMed, a leading commercialization partner.

Accelerating cancer vaccine against renal cell carcinoma

The aim of this letter of intent is to establish a strategic partnership that will drive Vaccntis' strategic and operational development. The focus is on the lead vaccine candidate VCC-001 and its platform technology. VCC-001 is a promising individualized therapeutic vaccine for the adjuvant treatment of renal cell carcinoma. The letter of intent states that TrueMed will support Vaccntis with its already built infrastructure and continuous search for potential strategic partnerships. Vaccntis grants exclusive rights for the commercialization, sale, and distribution of VCC-001 and future pipeline candidates in Israel for the duration of the agreement.

Combining Vaccntis' research and expertise and TrueMed's comprehensive competence in business development, investor relations, and strategic alliances is expected to significantly advance the next milestones for VCC-001.

Partnership with many joint opportunities

TrueMed and Vaccntis highly value their partnership and remain confident in the mutual opportunities that this collaboration will provide.

"VCC-001 is a promising immune therapy approach with enormous potential to fundamentally improve the treatment of cancer. With our many years of experience in market launch and commercialization, as well as our large investor network, we want to contribute to supporting Vaccntis in terms of research and development and hopefully bring the vaccine to patients as soon as possible," say Arie Koren and Shmulik Berkovich, co-CEOs and founders of TrueMed.

Vaccntis also emphasizes the importance of the collaboration to come: "TrueMed's support for our mission offers valuable opportunities to further accelerate the development of our product candidate VCC-001 and tumor vaccine platform technology. Gaining a sparring partner like TrueMed, which has years of expertise and a large network in the health-related financial community, can help us significantly in ensuring that the first patients will benefit from VCC-001 soon," state Vaccntis CEO Martin Munte and Vaccntis Member of the Board Patrik Grandits.

About Vaccntis

Vaccntis AG is a biotech and pharmaceutical company based in Zurich/Switzerland. The Swiss pharmaceutical company specializes in the development and manufacturing of individual cancer vaccines. The focus is on the development of therapeutic individualized tumor vaccines produced from the patient's own tumor – initially for renal cell carcinoma, with further indications to follow. Approval for the EU and USA is expected in the coming years. For further information, please visit vaccntis.com.

About TrueMed

TrueMed is a leading commercialization partner for rare disease and specialty care therapies in Israel. The company provides global innovators with a tailored, turnkey "port-to-patient" solutions, including early access, seamless market entry and patient and care partner support.

TrueMed has successfully partnered with leading U.S. and EU companies, launching locally some of the most innovative technologies, obtaining broad access, and delivering complex therapies to patients in great need. For more information, please visit www.TrueMedtx.com.

Press contact:

Brandenstein Communications

Related Sectors:

Medical & Pharmaceutical ::

Related Keywords:

Cooperation :: Biotech :: Vaccine :: Cancer ::

Scan Me:



Company Contact:

—

[news aktuell](#)

E. desk@newsaktuell.de

W. <https://www.newsaktuell.de/>

[View Online](#)

Newsroom: Visit our Newsroom for all the latest stories:

<https://www.newsaktuell.pressat.co.uk>